Biospecimen logistics for clinical trials

Biospecimen logistics for clinical trials is the temperature-controlled, chain-of-custody transport and storage of patient-derived samples — blood, tissue, and cells — between trial sites, central laboratories, and biorepositories. It is governed by GxP, Good Distribution Practice (GDP), and IATA temperature-control regulations, and it is scaling rapidly as cell-and-gene-therapy (CGT) trials and decentralized studies multiply. The segment is consolidating around GDP- and IATA CEIV Pharma-certified courier networks: Marken alone operates across 43 countries with some 1,406 staff and roughly GBP 168.9 million in annual revenue, PCI Pharma Services has committed over $1 billion to expand US and European capacity, and cryogenic storage now reaches −190°C for viable cell assets.

The key directions of biospecimen logistics are:

1. Cold-Chain Courier Networks: GDP- and IATA CEIV Pharma-certified couriers move time-critical, temperature-sensitive biospecimens across borders with validated packaging and real-time monitoring.
2. Cryogenic Storage & Biorepository: Automated cryogenic storage (down to −190°C) preserves viable cells, tissues, and CGT starting material across the research spectrum from discovery to therapeutic products.
3. Decentralized & Direct-to-Patient Trials: Home health visits and mobile phlebotomy shift sample collection closer to the patient, requiring last-mile cold-chain and integrated logistics platforms.
4. Chain-of-Custody Digital Tracking: IoT temperature loggers, barcode/RFID chain-of-custody, and electronic data capture link each sample to its analytical record without loss of identity.

Sectoral value chain#

[Collection] ──> [Packaging] ──> [Transport] ──> [Storage / Biorepository]
                              │
                      (Chain of Custody)
                              │
                              ▼
[Trial Data] <─── [Central Lab / Analytics] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Cold-Chain Courier Networks: GDP- and IATA CEIV Pharma-certified transport with validated thermal packaging and real-time temperature monitoring.
• Cryogenic Biorepository: Automated −150°C to −190°C storage for viable cells and CGT starting material.
• Chain-of-Custody Tracking: IoT loggers and barcode/RFID systems that preserve sample identity from draw to data.

The segment’s stack couples validated thermal packaging, IoT monitoring, and biorepository automation, all wrapped in GxP/GDP data integrity.

1. Cold-Chain Courier Networks:
   • GDP- and IATA CEIV Pharma-certified couriers move samples in validated shippers across controlled ambient, chilled, frozen, and cryogenic ranges.
   • Real-time temperature and location monitoring protects sample integrity across 43-country networks such as Marken’s.
2. Cryogenic Biorepository:
   • Automated cryogenic storage (down to −190°C, e.g. Azenta CryoArc) preserves viable cells and CGT starting material with sample-management software.
   • Enables long-term archive and retrieval for retrospective biomarker and longitudinal analyses.
3. Chain-of-Custody Tracking:
   • IoT loggers, barcode/RFID, and electronic data capture bind each biospecimen to its analytical and consent record end to end.
   • Underpins FDA 21 CFR Part 11 data-integrity expectations and audit-ready trial records.